Low vs Preserved SBP Following Cardiac Resynchronization Therapy
Assessing systolic blood pressure (SBP) 1 year after cardiac resynchronization therapy may improve patients’ long-term risk stratification, according to a new study.
To reach this conclusion, the researchers analyzed data on 1000 patients who had undergone cardiac resynchronization therapy implantation in the Multicenter Automatic Defibrillator Implantation With Cardiac Resynchronization Therapy (MADIT-CRT) study.
Outcomes were compared between patients with low SBP (<110 mm Hg) and preserved SBP (≥110 mm Hg) 1 year following the cardiac resynchronization therapy. At that time, 800 of the patients had preserved SBP.
At 1 year, patients with low SBP had a significantly higher rate of heart failure (HF) or mortality during subsequent follow-up compared with those who had a preserved SBP.
In fact, patients with preserved SBP at 1 year had a 29% lower risk of HF or mortality when compared with patients with low SBP.
“The association between SBP measured following cardiac resynchronization therapy implantation and subsequent clinical events was more pronounced among patients with nonischemic cardiomyopathy,” according to the researchers
Abdulla KH, Sherazi S, Goldenberg I, et al. Prognostic usefulness of systolic blood pressure one-year following cardiac resynchronization therapy (from MADIT-CRT). Am J Cardiol. 2020;125(5):777-782. https://doi.org/10.1016/j.amjcard.2019.11.023.